SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2025 financial results before the market opens...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations across its...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine...
04 Mar 2025
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial Officer and...
26 Feb 2025
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter and year ended...
24 Feb 2025
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial results before...
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progressionTop line data expected in the first half of 2026SILVER SPRING, Md. &...
First-ever human clinical trial of a xeno-organ intended to allow for potential registration through the submission of a Biologics License Application to the U.S. FDAFirst xenotransplant is expected to occur around...
Posters include real-world dosing of Tyvaso DPI® in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and data from the BREEZE open-label extension study of Tyvaso DPI...
06 Jan 2025
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperson and Chief...
The first living recipient of a UKidney™ is recovering after a successful transplantThis transplant builds on two successful UHeart™ transplants completed in 2022 and 2023 and a successful UThymoKidney™ transplant in...